Nasopharyngeal carcinoma (NPC) is a rare malignant tumor arising from epithelial cells of the nasopharynx. The study section "Nasopharyngeal Carcinoma" of the German Society of Pediatric Oncology and Hematology (GPOH) has been involved for many years in the development and optimization of treatment for this disease. In two major studies (NPC-91 and NPC-2003), which encompassed with 104 patients the highest number of children, adolescents and young adults treated in a prospective way, cure rates >90% were achieved applying a combination of chemotherapy, radiochemotherapy and maintenance treatment with interferon-ß. The current registry NPC-2016 collects data from patients with NPC, offers second opinion for diagnostic procedures and therapy by experts in the field of NPC, and receives biomaterial from patients for scientific research. The registry aims to ensure the highest level of quality for diagnosis and therapy by offering reference diagnostics and counseling, as well as to promote research on the pathogenesis and biological features of this tumor in order to identify targets for new therapies with higher efficacy and less adverse effects.
Prof. Udo Kontny